Arumakimig not checked
Novartis Pharmaceuticals · MAS825
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total · 4 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- Tested for
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- Main trialPhase 2
- “This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.”In the company’s words, NCT04641442 on ClinicalTrials.gov
- Other names
- MAS825
Other drugs for Still´s Disease
- FilgotinibAlfasigma S.p.A. · Phase 3
- GoflikiceptR-Pharm International, LLC · Phase 3
- OlokizumabR-Pharm International, LLC · Phase 3
- ApremilastAmgen · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- UpadacitinibAbbVie · Phase 3
Coming up2
- 22 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 14 Oct 2025 | Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations | |
| Phase 2Recruiting | 22 Apr 2027 | A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | |
| Phase 2Recruiting | 26 Dec 2028 | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period | |
| Phase 2Completed | 6 Jan 2021 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | |
| Phase 2Completed | 27 Oct 2024 | A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) | |
| Phase 2Completed | 4 Dec 2024 | Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 1Completed | 3 Aug 2022 | A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026